Class of antiretroviral drugs and the risk of myocardial infarction

New England Journal of Medicine

Volumn 356, Issue 17, 2007, Pages 1723-1735

  Friis Moller, Nina ^a   Reiss, Peter ^b   Sabin, Caroline A ^c   Weber, Rainer ^d   Monforte, Antonella D'Arminio ^e   El Sadr, Wafaa ^f   Thiebaut, Rodolphe ^g   De Wit, Stephane ^h   Kirk, Ole ^a   Fontas, Eric ⁱ   Law, Matthew G ^j   Phillips, Andrew ^c   Lundgren, Jens D ^a   Dabis, F ^k   Morfeldt, L ^k   Pradier, C ^k   Calvo, G ^k   Collins, S ^k   Loeliger, E ^k   Tressler, R ^k   Weller, I ^k   Worm, S W ^k   Sjol, A ^k   Sawitz, A ^k   Rickenbach, M ^k   Pezzotti, P ^k   Krum, E ^k   Gras, L ^k   Balestre, E ^k   Sundstrom, A ^k   Poll, B ^k   Torres, F ^k   Petoumenos, K ^k   Kjar, J ^k   more..

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY OF MILAN   (Italy)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g INSERM   (France)

^h SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

ⁱ CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^j UNIVERSITY OF NEW SOUTH WALES   (Australia)

^k NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; DRUG EXPOSURE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 34247537169     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa062744     Document Type: Article

References (29)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
2. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999;353:863-8.
3. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998;352:1725-30.
4. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999;341:1865-73.
5. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003. [Erratum, N Engl J Med 2004;350:955.]
6. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003;17:2479-86.
7. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360:1747-8.
8. Iloeje UH, Yuan Y, L'Italien G, et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 2005;6:37-44.
9. Mocroft A, Phillips AN, Friis-Moller N, et al. Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the Euro-SIDA study. Antivir Ther 2002;7:21-30.
10. Dieleman JP, Jambroes M, Gyssens IC, et al. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. AIDS 2002;16:737-45.
11. d'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS 2000;14:499-507.
12. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy: results from the DAD study. AIDS 2003;17:1179-93.
13. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994;90:583-612.
14. WHO MONICA Project. MONICA manual, part IV: event registration. Geneva: World Health Organization, 1999. (Accessed March 29, 2007, at http://www.ktl.fi/publications/monica/manual/part4/iv-1.htm.)
15. van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004;1:e19. [Erratum, PLoS Med 2004;1:e73.]
16. Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004;189:1056-74.
17. van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001;15:2407-14.
18. Zhou H, Pandak WM Jr, Lyall V, Natarajan R, Hylemon PB. HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease. Mol Pharmacol 2005;68:690-700.
19. Allred KF, Smart EJ, Wilson ME. Estrogen receptor-alpha mediates gender differences in atherosclerosis induced by HIV protease inhibitors. J Biol Chem 2006;281:1419-25.
20. Sax PE, Kumar P. Tolerability and safety of HIV protease inhibitors in adults. J Acquir Immune Defic Syndr 2004;37:1111-24. [Erratum, J Acquir Immune Defic Syndr 2004;37:1434.]
21. Saves M, Chene G, Ducimetiere P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003;37:292-8.
22. Pernerstorfer-Schoen H, Jilma B, Perschler A, et al. Sex differences in HAART-associated dyslipidaemia. AIDS 2001;15:725-34.
23. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003;33:506-12.
24. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96.
25. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74:1045-52.
26. Constans J, Pellegrin JL, Peuchant E, et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994;24:416-20.
27. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003;289:2978-82.
28. Phillips AN, Carr A, Neuhaus J, et al. Interruption of ART and risk of cardiovascular disease: findings from SMART. Presented at the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 26, 2007. abstract. (Accessed March 29, 2007, at http://www.retroconference.org/2007/ abstracts/28863.htm.)
29. Sabin C, Morfeldt L, Friis-Møller N, et al. Changes over time in antiretroviral therapy (ART) use and risk factors for cardiovascular disease (CVD) in the D:A:D study. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, Boston, February 25, 2005. abstract. (Accessed March 29, 2007, at http://www.retroconference.org/2005/cd/abstracts/25243.htm.)